Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 1 of his interview, part two can be viewed here.
1. What have been the most exciting recent developments in CAR-T cell therapy? (0:05)
2. Which patient subgroups are most likely to respond to this therapeutic approach? (1:40)
3. What are the major challenges in the manufacturing of CAR-T cells? (3:28)
Ibrahim El Houssieny has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Immunotherapy
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy
touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]
Rahul Aggarwal, ESMO 2021: Ceralasertib in ARID1A-deficient and ARID1A-intact Advanced Solid Tumour Malignancies
touchONCOLOGY joins Prof Rahul Aggarwal (UCSF School of Medicine, San Francisco, CA, USA), to discuss the interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumour malignancies. Questions 1. Could you tell us a little about ARID1A alterations in solid tumours and potential therapeutic targets in […]
David S Hong, ESMO 2021: Gavocabtagene Autoleucel Dose Escalation in Refractory Mesothelin-expressing Solid Tumors (PART TWO)
touchONCOLOGY joins Professor David S Hong (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) at ESMO 2021 to discuss the safety and activity of gavocabtagene autoleucel in a dose-escalation study in patients with refractory ovarian cancer, malignant mesothelioma, cholangiocarcinoma or non-small cell lung cancer. To view Part One, click here. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!